Researcher in Cardiovascular disease? Apply to this new €1,6M Competition for the next treatment

01/09/2015 - 2 minutes

A new research competition is born. The European Society of Cardiology and Boehringer Ingelheim will award €400k to four research projects treating cardiovascular diseases.

Big Pharmas like to give a push to aspiring research projects within their field. GSK is a key partner of the world’s largest life science startup accelerator, namely OneStart. Sanofi is engaged in new projects within diabetes research and also gives annual awards for scientists who have done outstanding medical research. Now, Boehringer Ingelheim joins the club to brace the search after cardiovascular medicines.

The new competitive research program is initiated by the European Society of Cardiology (ESC) and is called “ESC Grants for Medical Research Innovation”. With the support of Boehringer Ingelheim, four grants of up to €400,000 each will be awarded to research projects across the world.

“This grant project is a reflection of the ESC’s commitment to encouraging new and innovative research aimed at improving patient outcomes in thromboembolic disease – a leading cause of mortality worldwide,” said Professor Francesco Cosentino,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member